FDA-2025-P-4909

Requests that the FDA require updated labeling for Adequan (polysulfated glycosaminoglycan) with stronger contraindications and warnings regarding use in dogs with suspected or confirmed bleeding disorders, vascular cancers such as hemangiosarcoma, or peri-surgical settings, and to initiate a post-market safety review of Adequan’s anticoagulant properties